[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-cancer-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-cancer-recurrent":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,69,81,117,143,171,194,225,247,263,285,306,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053539","phase-1-a-clinical-study-of-raludotatug-deruxtecan-in-people-with-ovarian-cancer-mk-5909-003-100053539",false,"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","A Phase 1b\u002F2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy","Inclusion Criteria:\n\n* Has pathologically documented diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1\n* Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n* Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression \\\u003C6 months (\\\u003C180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen\n* Participants in Cohort B-1 and Cohort B-2: Is a candidate for bevacizumab treatment\n* Has provided tumor tissue from a core or excisional biopsy of a tumor lesion not previously irradiated\n* Has an Eastern Cooperative Oncology Group performance status of 0 to 1 assessed within 7 days before allocation\u002Frandomization\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy\n* Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants in Cohort C-1 and Cohort D: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with PARPi in the first-line setting\n* Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n\nExclusion Criteria:\n\n* Has any of the following within 6 months before allocation\u002Frandomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event\n* Has uncontrolled or significant cardiovascular disease\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy\n* Has ≥Grade 2 peripheral neuropathy\n* Has received prior treatment with cadherin-6-targeted agents\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation\n* Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Receives chronic steroid treatment\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active CNS metastases and\u002For carcinomatous meningitis\n* Has any history of interstitial lung disease (ILD)\u002Fpneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening\n* Has active infection requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease","FEMALE","18 Years",{"count":19,"type":20},460,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.\n\nStandard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include:\n\n* Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing\n* Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread\n\nRaludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.",[27],"Ovarian Cancer Recurrent","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-04-15",{"date":36,"type":20},"2029-03-27",{"name":38,"class":39},"Merck Sharp & Dohme LLC","INDUSTRY",27,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100054128","phase-2-sbrt-alone-or-followed-by-niraparib-for-oligometastases-or-oligoprogression-in-ovarian-cancer-following-parpi-therapy-100054128","NCT05990192","SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy","SOPRANO: Stereotactic Radiotherapy Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARP Inhibitor Therapy","SOPRANO","Inclusion Criteria:\n\n1. Patients ≥ 18 years of age.\n2. Histologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer. (if cytology report includes immunohistochemistry confirming ovarian cancer, patient should not be excluded).\n3. Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient's last systemic therapy.\n4. Minimum duration of 6 months PARP inhibitor therapy as first line therapy or treatment for recurrent disease.\n5. ≤3 lesions of progressive disease.\n6. Each lesion to undergo SBRT \\\u003C4 cm axial diameter, and feasible for SBRT as discussed in the SOPRANO virtual MDT (vMDT) meeting.\n7. Measurable disease by RECIST criteria v1.1, which can be accurately assessed at baseline by CT or MRI. Patients with CA125 progression in the absence of measurable disease will NOT be eligible. The following is an exception to this criterion: Lymph nodes with a short-axis diameter ≥10 mm may be included when there is clear evidence of malignancy (e.g., PET-positive nodes and radiologically progressive disease), acknowledging that clinically significant nodal disease may occur below the standard RECIST threshold.\n8. No contra-indication to restarting a PARP inhibitor.\n9. Patients for whom surgery for recurrent disease is not planned.\n10. Adequate baseline organ function to allow SBRT to all relevant targets as deemed by the investigator.\n11. ECOG performance status of 0 or 1.\n12. Predicted life expectancy ≥ 6 months.\n13. Women of child-bearing potential who are confirmed NOT to be pregnant. This should be evidenced by a negative urine or serum pregnancy test within 72 hours prior to start of trial treatment. Patients will be considered to be not of child-bearing potential if they are:\n\n    1. Post-menopausal -- defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, OR women under 50 years old who have been amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments and have serum follicle- stimulating hormone (FSH), luteinizing hormone (LH) and plasma oestradiol levels in the post-menopausal range for the institution.\n    2. Able to provide documentation of irreversible surgical sterilisation by hysterectomy, bilateral ovarian failure or bilateral salpingectomy but not tubal ligation.\n    3. Radiation or chemotherapy-induced oophorectomy or menopause with \\> 1 year since last menses.\n14. Willingness to commit to scheduled visits, treatments plans, laboratory tests and trial procedures.\n15. Histological tissue specimen (tissue block or 8-10 unstained slides) must be available prior to commencing SBRT (specimen can be the sample at diagnosis or taken at relapse or progression). Otherwise, a biopsy must be carried out to obtain sufficient tissue for translational analyses.\n16. Able to swallow, absorb and retain oral medication.\n17. Able to provide written, informed consent.\n\nExclusion Criteria:\n\n1. Co-morbidities which would preclude the safe use of SBRT.\n2. Progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or stereotactic radiosurgery. Previously treated brain metastases (i.e. palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for ≥ 6 months are permissible.\n3. Prior radiotherapy near the oligometastatic \u002F oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in Section 6.1 of this document and will be determined by the SOPRANO virtual MDT.\n4. Treatment with any other investigational medicinal product (IMP) within the 4 weeks prior to trial entry.\n5. Pregnant or lactating women.\n6. Women of childbearing age and potential who are not willing to use a highly effective contraceptive measure.\n7. Any unresolved toxicities from prior therapy should be no greater than CTCAE Grade 1 with the exception of Grade 2 alopecia or chemo-induced neuropathy at trial entry.\n8. Clinical\u002Fradiological evidence of bowel obstruction (e.g. hospitalisation) or symptoms of sub-acute bowel obstruction within 6 weeks prior to trial entry.\n9. Any other malignancy which has been active or treated within the past 3 years, with the exception of non-melanoma skin cancer. If prior treatment for another malignancy has taken place, then confirmation of ovarian\u002Ffallopian tube\u002Fperitoneal cancer progression is required e.g. biopsy, and discussion with the trial Chief Investigator and SBRT Lead\n10. Judgment by the Investigator that the patient is unsuitable to participate in the trial and\u002For the patient is unlikely to comply with trial procedures, restrictions and requirements.",{"count":50,"type":20},42,[24],"SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.",[27],[55,56,57,58,59],"Ovarian Cancer","Oligoprogressive","Oligometastatic","SBRT","PARP Inhibitor",{"date":31,"type":32},{"date":62,"type":32},"2024-06-20",{"date":64,"type":20},"2027-12-31",{"name":66,"class":67},"Institute of Cancer Research, United Kingdom","OTHER",7,{"id":70,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":25,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":79,"locationsCount":80},"100580910",{"count":19,"type":20},[23,24],[27],"2026-06-24",{"date":76,"type":32},"2026-06-26",{"date":34,"type":32},{"date":36,"type":20},{"name":38,"class":39},26,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100644293","phase-1-a-phase-1-study-to-evaluate-the-safety-and-efficacy-of-opb-201-in-recurrent-endometrial-and-platinum-resistant-ovarian-cancer-100644293","NCT07664735","A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","A Phase 1a\u002Fb Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at the time of signing the informed consent form.\n2. Histologically confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.\n3. Received at least 1 prior line of systemic chemotherapy including a platinum-based chemotherapy.\n4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1\u002F2 mutation.\n5. Measurable disease.\n6. Consent to provide archived tumor tissue sample.\n7. ECOG performance status of 0 or 1.\n8. Adequate organ function.\n9. HLA-A \\*02:01 or HLA-A \\*02:02\n10. PRAME positive tumor\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Uncontrolled bacterial, fungal, or viral infections.\n3. Active infection requiring systemic therapy.\n4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.\n5. Any form of primary immunodeficiency.\n6. Had an allogenic tissue\u002Fsolid organ transplant.\n7. Active autoimmune disease.\n8. Concurrent treatment with systemic high dose corticosteroids.\n9. Unresolved acute effects of any prior therapy.\n10. Other exclusions as stated in the protocol.",{"count":89,"type":20},30,[23],"The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.",[93,94,95,55,27,96,97],"Endometrial Cancer Recurrent","Endometrial Cancer","Advanced Endometrial Cancer","Platinum Resistant Ovarian Cancer","Endometrial Cancers",[99,100,101,102,103,104,105,106,107],"Outpace","Ovarian cancer","Endometrial cancer","advanced ovarian cancer","advanced endometrial cancer","cell therapy","TCR-T","TCR","PRAME directed TCR","NOT_YET_RECRUITING","2026-06-17",{"date":74,"type":32},{"date":112,"type":20},"2026-06-30",{"date":114,"type":20},"2030-09",{"name":116,"class":39},"Outpace Bio, Inc.",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100584406","phase-1-a-clinical-trial-to-evaluate-the-safety-and-efficacy-of-com701-in-relapsed-platinum-sensitive-ovarian-cancer-100584406","NCT06888921","A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)","MAIA-ovarian","Inclusion Criteria:\n\n* Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer\n* Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy\n* For the last chemotherapy course prior to being randomized into the study, must have had a minimum of 4 cycles of a platinum containing regimen and achieved a partial or complete tumor response.\n* Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bevacizumab or PARP inhibitor therapy.\n* Have recovered from toxicities of prior chemotherapy or other therapy (to grade 1 or less, except for alopecia and neuropathy recovered to a ≤grade 2).\n\nExclusion Criteria:\n\n* Has had 4 or more lines of cytotoxic chemotherapy in total\n* Is being treated with immunosuppressive doses of systemic medications, such as steroids within 2 weeks before study drug administration\n* Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors\n* Presence of radiographic or biopsy proven liver metastases at the beginning or completion of current line of platinum-based chemotherapy.\n* Drainage of ascites during last 2 cycles of last chemotherapy or any time after completion of the last chemotherapy regimen.\n* Bowel obstruction in the 6 weeks prior to randomization.\n* Have known active central nervous system metastases and\u002For carcinomatous meningitis \u002F leptomeningeal carcinomatosis.\n* Has active hepatitis B virus (HBV) or hepatitis C virus (HCV), or subjects with human immunodeficiency virus (HIV).\n* Has active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.\n* Has received a live viral vaccine within 30 days of planned start of study treatment or requiring a live vaccine during the study.\n* Has a history of severe allergic, anaphylactic, or other hypersensitivity reactions to a human or humanized monoclonal antibody (mAb) or allergy to any excipients in the investigational products.\n* Has any serious or unstable concomitant systemic disorder\n* Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the subject inappropriate for entry into the study.\n* Is currently participating in or have participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Is pregnant or breastfeeding or planning to become pregnant during the period of the study.",{"count":126,"type":20},60,[23,24],"The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701.\n\nThe main questions the trial aims to answer are:\n\n* Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer?\n* Does COM701 delay the time to needing a new anti-cancer treatment?\n* What side effects do participants have when taking COM701?\n\nParticipants will:\n\n* Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously\n* Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant.\n* Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,",[55,27],[131,132],"maintenance therapy","relapsed platinum sensitive ovarian cancer","2026-03-31",{"date":135,"type":32},"2026-04-01",{"date":137,"type":32},"2025-07-21",{"date":139,"type":20},"2027-03",{"name":141,"class":39},"Compugen Ltd",28,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100615632","phase-2-rescue-study-recurrent-ovarian-cancer-secondary-cytoreduction-using-chemotherapy-response-100615632","NCT07295132","RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)","A Randomized Clinical Trial Evaluating the Role of Secondary Cytoreductive Surgery Following Neoadjuvant Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: Patient Selection Informed by CA-125 Response Dynamics During Chemotherapy (RESCUE Study)","Inclusion Criteria:\n\n* First recurrence of platinum-sensitive, invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of initial stage.\n* A progression-free interval of at least 6 months after the end of the last platinum-containing regimen.\n* Demonstrated response during neoadjuvant chemotherapy after recurrence (Complete Response\u002FPartial Response\u002FStable Disease according to RECIST 1.1 or GCIG CA-125 response, which is a ≥50% reduction in pre-treatment CA-125 level sustained for ≥28 days).\n* Women aged 19 years or older.\n* The tumor is judged to be completely resectable by surgery (R0) based on the judgment of an experienced surgeon\n* Patients who provide signed and written informed consent and consent to data transfer and processing.\n\nExclusion Criteria:\n\n* Patients without recurrence\n* Patients with non-epithelial tumors or borderline tumors.\n* Patients with second, third, or subsequent recurrence.\n* Patients with a secondary malignancy treated with laparotomy and other neoplasms, where the treatment is expected to interfere with the treatment of recurrent ovarian cancer or significantly affect prognosis.\n* Patients with platinum-refractory tumors (i.e., progression during chemotherapy or recurrence within 6 months after the end of the previous first platinum-containing regimen).\n* Cases where only palliative surgery is planned.\n* Radiological signs suggestive of metastasis that are considered completely unresectable.\n* Any comorbidity that precludes surgery and\u002For chemotherapy (e.g., poor general condition, severe infection, conditions that may cause severe bleeding, severe renal disease, etc.).\n* Any medical history that may cause excessive surgical risk pre- or post-operatively.\n* Medications being taken that pose a significant surgical risk (e.g., oral anticoagulants, bleeding risk due to bevacizumab).\n* Absence of evaluable archived tumor tissue.","19 Years",{"count":152,"type":20},160,[24],"This is a multicenter, prospective, randomized, open-label Phase III clinical trial (RESCUE study) evaluating the efficacy of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have shown a favorable response to 3-4 cycles of platinum-based neoadjuvant chemotherapy and are assessed as highly likely to achieve complete tumor resection based on selection models. Eligible patients will be randomly assigned to either the experimental arm, receiving SCS followed by chemotherapy (with or without maintenance), or the active comparator arm, receiving chemotherapy only (with or without maintenance), with the primary objective being to compare the Progression-Free Survival (PFS) between the two groups to determine the additional clinical benefit of SCS in this carefully selected patient population.",[27,156],"Platinum Sensitive Ovarian Cancer",[158,159,160,161],"platinum sensitive recurrent ovarian cancer","secondary cytoreductive surgery","neoadjuvant chemotherapy","CA-125 response","2025-12-16",{"date":164,"type":32},"2025-12-19",{"date":166,"type":20},"2025-12-15",{"date":168,"type":20},"2029-11-15",{"name":170,"class":67},"Asan Medical Center",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100595319","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-opb-101-in-platinum-resistant-ovarian-cancer-100595319","NCT07030907","A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","A Phase 1a\u002Fb Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at the time of signing the informed consent form.\n2. Histologically confirmed diagnosis of high grade serous epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.\n3. Recurrent platinum-resistant disease defined as: Disease that has recurred within 6 months of the last receipt of platinum-based therapy.\n4. Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.\n5. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1\u002F2 mutation.\n6. Measurable disease.\n7. Consent to provide archived tumor tissue sample.\n8. ECOG performance status of 0 or 1.\n9. Adequate organ function.\n10. Alkaline phosphatase ≤ 2.5 x ULN\n11. ≤ Grade 1 dyspnea and oxygen saturation levels (SpO2) \\> 92% on room air.\n12. LVEF ≥ 50%\n13. Life expectancy of ≥ 3 months\n14. Adequate venous access.\n15. Negative screen for infectious disease markers.\n16. Negative serum pregnancy test.\n17. Abstain from heterosexual activity or to use 2 forms of effective methods of contraception.\n\nNote: Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Uncontrolled bacterial, fungal, or viral infections.\n3. Active infection requiring systemic therapy.\n4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.\n5. Any form of primary immunodeficiency.\n6. Had an allogenic tissue\u002Fsolid organ transplant.\n7. Active autoimmune disease.\n8. Concurrent treatment with systemic high dose corticosteroids.\n9. Unresolved acute effects of any prior therapy.\n10. Active invasive cancer other than the cancer under study.\n11. Significant lung disease.\n12. Clinically significant pericardial effusion.\n13. Prior radiotherapy within 2 weeks of start of study intervention.\n14. No major surgery within 28 days prior to enrollment.\n15. Received investigational agents or tumor vaccines.\n16. Received chemotherapy within the previous 3 weeks.\n17. History of grade ≥ 3 ascites.\n18. Active CNS involvement.\n19. Received a live vaccine within 30 days prior to study treatment.\n20. Received prior CAR T cell therapy.\n21. Received prior mesothelin targeted therapy.\n22. Dependent on intravenous hydration or total parenteral nutrition. Note: Other protocol defined exclusion criteria could apply",{"count":89,"type":20},[23],"The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.\n\nParticipants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.",[27,55,96],[99,100,183,104,184],"Advanced ovarian cancer","CAR T","2025-12-11",{"date":187,"type":32},"2025-12-18",{"date":189,"type":32},"2025-06-16",{"date":191,"type":20},"2030-05-15",{"name":116,"class":39},4,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100576119","a-study-to-explore-personalized-treatment-for-patients-with-recurrent-gynecological-malignancies-based-on-mtb-100576119","NCT06781151","A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB","A Real-world Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on Molecular Profiling and Multidisciplinary Team Consultation","RWS-MTB","Inclusion Criteria:\n\n* Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist;\n* Presence of at least one evaluable lesion;\n* Willingness to participate in multidisciplinary consultation;\n* Age 18 years or older;\n* Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%;\n* Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate.\n\nExclusion Criteria:\n\n* Patients with concurrent malignancies;\n* Pregnant patients.",{"count":203,"type":20},200,"2 Years","OBSERVATIONAL","This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study.\n\nThe main question it aims to answer is:\n\nWill genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? The retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution from January 2022 onward. Data collected will include tumor tissue genomic sequencing results, medical histories, multidisciplinary consultation recommendations, and subsequent treatment courses. This analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation.\n\nThe prospective arm will enroll 200 patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) referred for multidisciplinary consultation. Tumor tissue and blood samples will undergo next-generation sequencing (NGS) to determine molecular tumor profiles. A multidisciplinary expert panel will formulate individualized treatment strategies based on these profiles, patient clinical data, and treatment history. Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling and multidisciplinary consultation.",[27,93,208],"Cervical Cancer Recurrent",[210,211,212,213,214],"genomic sequencing","molecular tumor boards","recurrent ovarian cancer","recurrent endometrial cancer","recurrent cervical cancer","2025-08-20",{"date":217,"type":32},"2025-08-27",{"date":219,"type":32},"2024-04-24",{"date":221,"type":20},"2027-06-18",{"name":223,"class":67},"Sun Yat-sen University",2,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100517206","phase-2-in10018-in-combination-with-pegylated-liposomal-doxorubicin-pld-vs-placebo-in-combination-with-pld-for-the-treatment-of-platinum-resistant-recurrent-ovarian-cancer-100517206","NCT06014528","IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign informed consent(s). Signed informed consent must be obtained before any study specific procedures, except those procedures used as institutional standard of care falling into the protocol specified window and fulfilling study specific requirements such as tumor imaging.\n2. Female subjects ≥ 18 years at the time of signing informed consent.\n3. Histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer and its subtype is high-grade serous carcinoma (HGSC).\n4. Have received platinum containing therapy and have radiological relapse or progression during platinum containing treatment or \\\u003C 6 months (184 calendar days) after completion of prior platinum-based therapy (at least 4 cycles).\n\n   Note: Disease progression or recurrence requires evidence of radiographic or clinical progression (e.g., new ascites or cytological reports of pleural fluid), and elevated CA125 alone is not a criterion for progression or recurrence. Primary platinum-refractory ovarian cancers (defined as progression during or within 4 weeks after first line platinum-based therapy) is excluded, while secondary platinum-refractory disease is allowed and does not require at least 4 cycles of platinum-based therapy.\n5. Maximum total of 3 prior lines of systemic therapy are allowed. Note: Hormonal therapies (e.g., tamoxifen), PARP inhibitors and bevacizumab given in the maintenance setting post response to platinum-based therapy will not count as a treatment line. Other maintenance regimens may also not count as a treatment line by discussion between the investigator and sponsor.\n6. At least one measurable lesion can be accurately measured per RECIST 1.1 as assessed by investigator.\n\n   Note: Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n7. ECOG performance status of 0 or 1.\n8. Life expectancy of at least 3 months as assessed by investigator.\n9. Availability of archival or fresh (newly obtained) tumor tissue sample during screening phase: fresh tumor tissue sample obtained after most recent relapse or progression is preferred; if no sample or not sufficient number of slides (refer to Laboratory Manual which will be provided separately) can be provided or collected, a joint decision between sponsor and investigator is needed for the enrollment of this subject.\n10. Must have recovered from all AEs due to previous therapies to ≤ Grade 1 (CTCAE 5.0) or stable status as assessed by investigator.\n\n    Note: subjects with minor toxicities with no safety concern like alopecia and Grade 2 neuropathy could be enrolled per evaluation of investigator.\n11. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to randomization.\n\n    1. Hemoglobin (Hb) ≥ 100 g\u002FL (10 g\u002FdL), independent of blood infusion, red blood cell transfusion and erythropoietin (EPO) use within 14 days prior to the screening period examination.\n    2. Platelet count ≥ 100 × 109\u002FL, independent of platelet infusion within 14 days prior to the screening period examination.\n    3. Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, independent of colony stimulating factor (CSF) use within 14 days prior to the screening period examination.\n    4. Total bilirubin ≤ upper limit of normal (ULN).\n    5. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for subjects with documented liver involvement of their disease).\n    6. Serum creatinine ≤ 1.5 × ULN, Estimated Creatinine clearance rate (Clcr) by the Cockcroft-Gault (C-G) equation ≥ 60 mL\u002Fmin or estimated glomerular filtration rate (eGFR) from the Modification of Diet in Renal Disease (MDRD) equation ≥ 60 mL\u002Fmin.\n    7. Urinary protein negative or trace (±); or urinary protein ≥ 1+ but with a urine protein to creatinine ratio (UPCR) in a morning spot urine sample \\\u003C 0.5 or a 24-hour urine protein \\\u003C 0.5 g\u002F24 h.\n    8. International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN. Subjects with stable anticoagulation treatment is allowed.\n12. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    1. Not a woman of childbearing potential (WOCBP) as defined in section 10.4 Appendix 4 of the full protocol.\n\n       OR\n    2. A WOCBP who agrees to follow the contraceptive guidance in section 10.4 Appendix 4 of the full protocol during the treatment period and through 3 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Has had major surgery or significant traumatic injury within 28 days prior to randomization, or diagnostic biopsies within 14 days prior to randomization.\n\n   Note: Subjects with anticipation of the need for major surgery during study treatment should be excluded. Subjects who underwent diagnostic biopsy within 14 days prior to randomization may also be enrolled if the investigator and sponsor determine that the diagnostic biopsy will not affect the efficacy evaluation.\n2. Has received prior systemic anticancer therapy including investigational agents, such as within 14 days or less than 5 half-lives (whichever is shorter) of chemotherapy or targeted therapy, or within 28 days of immunotherapy, macromolecular drugs (eg., bevacizumab) or investigational drugs prior to randomization.\n3. Has received prior radiotherapy within 14 days prior to randomization. Note: A 7-day washout is permitted for palliative radiation (≤ 14 days of radiotherapy) to non-central nervous system (CNS) disease.\n4. Has received prior treatment of any FAK inhibitor or prior treatment of PLD.\n5. Has a known previous or concurrent cancer that is distinct in primary site or histology from current ovarian cancer within 3 years prior to randomization, except for curatively treated cancers such as cervical\u002Fbreast\u002Fprostate carcinoma in situ and basal cell carcinoma.\n6. Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n\n   Note: Subjects with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks apart by repeat imaging (note that the repeat imaging should be performed during screening phase) for at least 28 days prior to randomization.\n7. Has a history of major cardiovascular, cerebrovascular or thromboembolic diseases (e.g., congestive heart failure, acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep vein thrombosis or pulmonary embolism) within 6 months before randomization, or has any of the following abnormality:\n\n   1. QTc interval corrected using Fridericia's formula \\> 470 ms (based on QTcF).\n   2. Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n   3. New York Heart Association (NYHA) functional classification ≥ Grade 2.\n   4. Clinically significant arrhythmia.\n   5. Uncontrolled hypertension or diabetes.\n   6. Other clinically significant heart diseases.\n8. Has known pleural effusion, pericardial effusion or ascites accompanied by clinical symptoms or requiring puncture or drainage. Subjects who received drainage within the first 3 months of randomization should be excluded. A small amount of ascites that can only be detected by imaging examination and without clinical symptom is allowed.\n9. Has malabsorption syndrome or inability to take oral drugs.\n10. Has clinically significant gastrointestinal abnormalities including uncontrolled gastrointestinal inflammatory lesions (Crohn's disease, or ulcerative colitis in active) or uncontrolled gastrointestinal bleeding.\n11. Clinical or radiographic evidence of intestinal obstruction, or aetiology of previous recurrent ileus not excluded.\n12. Currently have interstitial pneumonia (except for radiation pulmonary fibrosis that does not require hormonal therapy).\n13. Has not well controlled active infection after systemic therapy.\n14. Has known human immunodeficiency virus (HIV) infection or known active Hepatitis B or Hepatitis C virus infection.\n\n    Note: No HIV, Hepatitis B and Hepatitis C testing is required unless mandated by local health authority and\u002For site.\n15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n16. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.\n17. Known allergy or hypersensitivity to IN10018 or PLD, or their ingredients.\n18. Has received prior cumulative anthracycline dose of 550 mg\u002Fm2 or more.\n19. Has received systemic treatment of CYP3A4, CYP2D6 or P-gp strong inhibitors\u002Finducers within 14 days prior to randomization, or anticipation of the systemic treatment of these drugs during Treatment Phase.",{"count":233,"type":20},168,[24],"This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).",[27],"2025-04-28",{"date":239,"type":32},"2025-04-30",{"date":241,"type":32},"2022-09-06",{"date":243,"type":20},"2026-12-24",{"name":245,"class":39},"InxMed (Shanghai) Co., Ltd.",1,{"id":248,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":262},"100515337","Inclusion Criteria:\n\n1. Patients ≥ 18 years of age.\n2. Histologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer.\n3. Radiological disease progression whilst on, or following, any prior PARP inhibitor therapy. The PARP inhibitor is required to have been the patient's last systemic therapy.\n4. Minimum duration of 6 months PARP inhibitor therapy as first line therapy or treatment for recurrent disease.\n5. ≤3 lesions of progressive disease.\n6. Each lesion to undergo SBRT \\\u003C4 cm axial diameter, and feasible for SBRT as discussed in the SOPRANO virtual MDT (vMDT) meeting.\n7. Measurable disease by RECIST criteria v1.1, which can be accurately assessed at baseline by CT or MRI. Patients with CA125 progression in the absence of measurable disease will NOT be eligible.\n8. No contra-indication to restarting a PARP inhibitor.\n9. Patients for whom surgery for recurrent disease is not planned.\n10. Adequate baseline organ function to allow SBRT to all relevant targets as deemed by the investigator.\n11. ECOG performance status of 0 or 1.\n12. Predicted life expectancy ≥ 6 months.\n13. Women of child-bearing potential who are confirmed NOT to be pregnant. This should be evidenced by a negative urine or serum pregnancy test within 72 hours prior to start of trial treatment. Patients will be considered to be not of child-bearing potential if they are:\n\n    1. Post-menopausal -- defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, OR women under 50 years old who have been amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments and have serum follicle- stimulating hormone (FSH), luteinizing hormone (LH) and plasma oestradiol levels in the post-menopausal range for the institution.\n    2. Able to provide documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.\n    3. Radiation or chemotherapy-induced oophorectomy or menopause with \\> 1 year since last menses.\n14. Willingness to commit to scheduled visits, treatments plans, laboratory tests and trial procedures.\n15. Histological tissue specimen (tissue block or 8-10 unstained slides) must be available prior to commencing SBRT (specimen can be the sample at diagnosis or taken at relapse or progression). Otherwise, a biopsy must be carried out to obtain sufficient tissue for translational analyses.\n16. Able to swallow, absorb and retain oral medication.\n17. Able to provide written, informed consent.\n\nExclusion Criteria:\n\n1. Co-morbidities which would preclude the safe use of SBRT.\n2. Progressing or newly diagnosed brain metastases identified at the time of trial entry, not amenable to radical surgery or stereotactic radiosurgery. Previously treated brain metastases (i.e. palliative radiotherapy or systemic therapy) which have remained clinically and radiologically stable for ≥ 6 months are permissible.\n3. Prior radiotherapy near the oligometastatic \u002F oligoprogressive lesion precluding ablative SBRT. Suitability of lesions for ablative SBRT as part of the trial defined in Section 6.1 of this document and will be determined by the SOPRANO virtual MDT.\n4. Treatment with any other investigational medicinal product (IMP) within the 4 weeks prior to trial entry.\n5. Pregnant or lactating women.\n6. Women of childbearing age and potential who are not willing to use a highly effective contraceptive measure.\n7. Any unresolved toxicities from prior therapy should be no greater than CTCAE Grade 1 with the exception of Grade 2 alopecia or chemo-induced neuropathy at trial entry.\n8. Clinical\u002Fradiological evidence of bowel obstruction (e.g. hospitalisation) or symptoms of sub-acute bowel obstruction within 6 weeks prior to trial entry.\n9. Any other malignancy which has been active or treated within the past 3 years, with the exception of non-melanoma skin cancer. If prior treatment for another malignancy has taken place, then confirmation of ovarian\u002Ffallopian tube\u002Fperitoneal cancer progression is required e.g. biopsy, and discussion with the trial Chief Investigator and SBRT Lead\n10. Judgment by the Investigator that the patient is unsuitable to participate in the trial and\u002For the patient is unlikely to comply with trial procedures, restrictions and requirements.",{"count":50,"type":20},[24],"SOPRANO is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.",[27],[55,56,57,58,59],"2025-04-17",{"date":257,"type":32},"2025-04-22",{"date":62,"type":32},{"date":260,"type":20},"2027-06-30",{"name":66,"class":67},5,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":273,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":283,"locationsCount":246},"100576912","phase-2-pegylated-liposomal-doxorubicin-plus-adebrelimab-with-or-without-mirabegron-in-relapsed-ovarian-cancer-100576912","NCT06791460","Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer","Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial","Inclusion Criteria:\n\n* Has provided documented informed consent for the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.\n* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).\n* Has a platinum-free interval (PFI) of \\\u003C 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of \\\u003C 12 months if the last regimen received is a non-platinum-based.\n* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Has a life expectancy of ≥12 weeks.\n* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.\n* Has adequate organ function.\n* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.\n\nExclusion Criteria:\n\n* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.\n* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 \\[CTLA-4\\], tumor necrosis factor receptors OX-40 or CD137) or has participated in prior adebrelimab studies.\n* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before randomization.\n* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients.\n* Has undergone major surgery within 3 weeks before randomization or has complications\u002Fsequelae that have not yet recovered.\n* Has a known additional malignancy that progressed or required active treatment within the last 5 years.\n* Is pregnant or breastfeeding.\n* Has a history of allogenic tissue\u002Fsolid organ transplant.\n* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.\n* Has a history of active autoimmune disease.\n* Has an active infection requiring systemic therapy.\n* Has a history of human immunodeficiency virus (HIV) infection.\n* Has a history of Hepatitis B or C virus infection.\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.","75 Years",{"count":272,"type":20},296,[24,274],"PHASE3","The goal of this clinical trial is to learn if drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron. The main questions it aims to answer are:\n\nDoes drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron reduce tumor volume? What medical problems do participants have when taking drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron?\n\nResearchers will compare drug regimen pegylated liposomal doxorubicin and adebrelimab with mirabegron to a drug regimen pegylated liposomal doxorubicin and adebrelimab without mirabegron to see which drug regimen works better to treat relapsed ovarian cancer.\n\nParticipants will:\n\nTake drug pegylated liposomal doxorubicin and adebrelimab every 21 days with or without everyday mirabegron Visit the clinic once every 2 months for checkups and tests Keep a diary of their symptoms",[27],"2025-03-17",{"date":279,"type":32},"2025-03-18",{"date":279,"type":20},{"date":282,"type":20},"2030-02-14",{"name":284,"class":67},"Obstetrics & Gynecology Hospital of Fudan University",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":246},"100566848","early-phase-1-exploratory-study-on-the-safety-and-efficacy-of-disitamab-vedotin-in-combination-with-anlotinib-hydrochloride-for-the-treatment-of-her-2-expressing-recurrent-platinum-resistant-ovarian-cancer-100566848","NCT06660511","Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.","Inclusion Criteria:\n\n1. The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n2. Age ≥ 18 years old when signing the informed consent form;\n3. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by organizational or cellular pathology;\n4. The subjects can provide tumor primary or metastatic site specimens for HER2 detection (paraffin blocks, paraffin embedded sections, or fresh tissue sections are all acceptable), and the immunohistochemical (IHC) test results show HER2 expression: IHC 1+, 2+, or 3+; 4) ECOG PS: 0-1 point;\n5. Expected survival period\\>12 weeks;\n6. Adequate heart, bone marrow, liver, and kidney function (based on normal values at the research center);\n7. At least one measurable lesion defined in RECIST version 1.1;\n8. Women of childbearing age must meet one of the following conditions:\n\n   * Surgical sterilization has been performed; ② Menopausal individuals who have stopped menstruating for at least one year; ③ Having the ability to conceive requires meeting the following conditions:; The serum pregnancy test result before the first medication is negative and must be a non lactating subject; During the entire study period, it was agreed to use a recognized method of contraception (such as oral contraception, injection contraception, or implanted barrier contraception, spermicides and condoms, or intrauterine devices), and the contraceptive method remained unchanged throughout the study period.\n\nExclusion criteria：\n\n1. Previously received ADC drugs for HER2 treatment or similar TKI small molecule anti angiogenic drugs such as anlotinib hydrochloride;\n2. Subjects with primary platinum refractory diseases;\n3. Patients with untreated central nervous system metastases (including new and progressive brain metastases), a history of leptomeningeal metastases or malignant meningitis;\n4. Individuals with symptoms and signs of intestinal obstruction and requiring parenteral nutrition and fluid replacement;\n5. Patients with any signs of bleeding or history of bleeding, regardless of the severity: patients who have experienced any bleeding or bleeding events ≥ CTCAE grade 3 within the 4 weeks prior to the first dose; Or there may be unhealed wounds, fractures, active ulcers in the stomach and duodenum, ulcerative colitis and other digestive diseases.\n6. Within 6 months, there have been incidents of arterial\u002Fvenous thrombosis, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; (Individuals with a tendency towards thrombosis or undergoing anticoagulant therapy are allowed to use prophylactic anticoagulant therapy)\n7. Serious cardiovascular and cerebrovascular diseases or discomfort, including but not limited to the following diseases:\n\n   * Diagnosed history of heart failure or systolic dysfunction (LVEF\\\u003C50%)\n   * High risk uncontrolled arrhythmia\n   * Angina pectoris, acute myocardial infarction\n   * Clinically significant heart valve disease\n   * Poor control of hypertension (systolic blood pressure\\>180 mmHg and\u002For diastolic blood pressure\\>100 mmHg)\n8. The toxicity caused by previous anti-tumor treatments has not yet recovered to CTCAE (version 5.0) grade 0-1 (excluding 2nd degree hair loss);\n9. Individuals who have undergone major surgery within 4 weeks prior to their first medication and have not fully recovered, or are expected to undergo surgical treatment;\n10. Patients with other malignant tumors within 3 years prior to the first use of medication, excluding papillary thyroid carcinoma, basal cell or squamous cell carcinoma that have been adequately treated and have no evidence of disease recurrence, as well as other in situ cancers that have been adequately treated and have no evidence of disease recurrence (including but not limited to cervical primary cancer, ductal carcinoma in situ of the breast, etc.);\n11. Imaging (CT or MRI) shows that the tumor has invaded important blood vessels or is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies, as determined by the researcher;\n12. Patients with clinical symptoms of pleural effusion, pericardial effusion, or ascites who require repeated puncture and drainage, or those who have received treatment within the previous month for the purpose of drainage;\n13. Individuals with a known history of allergies to the components of this medication regimen;\n14. Pregnant and lactating female patients;\n15. Suffering from serious accompanying diseases or other comorbidities that may interfere with planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study",{"count":262,"type":20},[293],"EARLY_PHASE1","Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction surgery and postoperative chemotherapy, 70% to 80% of ovarian cancer patients still experience recurrence. According to the length of PFI (platinum free interval), recurrent ovarian cancer (ROC) can be classified into platinum resistant ROC (\\\u003C6 months) and platinum sensitive ROC (\\>6 months). There is currently no optimal treatment plan for platinum resistant ovarian cancer (PROC), and the prognosis for patients is poor. The guidelines recommend non platinum monotherapy chemotherapy for patients with PROC, but non platinum monotherapy has a low objective response rate (ORR) (\\\u003C20%), progression free survival (PFS) (\\\u003C4 months), and overall survival (OS,\\\u003C12 months), with significant adverse reactions and affecting quality of life. Therefore, PROC patients urgently need new and better treatment options.\n\nAntibody conjugated drugs (ADCs) have made breakthrough therapeutic progress in multiple tumor types, and currently ADCs have been approved by the FDA for the treatment of cervical cancer and ovarian cancer. HER2 (Human Epidermal Growth Factor Receptor 2) is a member of the epidermal growth factor receptor (EGFR) family, also known as the tyrosine protein kinase receptor. Research has shown that HER2 expression is associated with poor prognosis in ovarian cancer, and patients with HER2 positive expression have a worse prognosis. Vidiximab (RC48) is a novel HER2 antibody conjugate drug that received Breakthrough Therapy Design from the US Food and Drug Administration (FDA) in April 2020. Preclinical studies of ovarian cancer have shown that vediximab exhibits effective cytotoxicity against HER2 expressing ovarian tumor cell lines. Meanwhile, the registration study of RC48 for gynecological tumors is underway, and its latest data was reported at the 2024 European Congress of Gynecological Oncology (ESGO), which showed that in patients with recurrent or metastatic cervical cancer, the ORR of RC48 monotherapy was 36.4%, the median PFS was 4.37 months, and the 1-year OS was 66%. Compared to other chemotherapy drugs, it also has significant advantages in terms of toxic side effects, with severity mostly ranging from grade 1-2. Symptomatic treatment can achieve complete recovery or relief.\n\nAnti angiogenic drugs, including anti vascular endothelial growth factor (VEGF) antibodies and multi-target tyrosine kinase inhibitors (TKIs), are considered potential targets for treating platinum resistant\u002Frefractory ovarian diseases . Anlotinib is a novel oral multi-target tyrosine kinase inhibitor (TKIs) . Monotherapy for PROC has achieved initial efficacy, with an ORR of 31.2%, a median PFS of 5.3 months, and a 12-month OS rate of 90.9%. In terms of safety, most of the toxic side effects are grade 1-2.\n\nGood progress has been made in preclinical and clinical trials of ADC in combination with other anti-cancer drugs, including chemotherapy, molecular targeted drugs, anti angiogenic drugs, and immunotherapy. Among them, anti angiogenic drugs may promote the penetration and exposure of ADC to tumor cells, playing a mutually reinforcing role. Research on the combination of RC48 and anlotinib is also actively underway in other tumor types.\n\nIn summary, this study creatively conducted exploratory research in clinical PROC patients based on the different expression levels of the molecular target HER2, and adopted targeted medication according to the molecular target. At the same time, in terms of combination therapy, low toxicity and high efficiency, different toxic side reaction spectra, different mechanisms of action, and synergistic effects of dual anti-tumor drugs were selected for combination therapy. Based on the above evidence, an exploratory study was conducted on the safety and efficacy of vediximab combined with anlotinib in the treatment of HER-2 expressing recurrent platinum resistant ovarian cancer, aiming to explore the efficacy of vediximab combined with anlotinib in PROC patients, in order to further improve the remission rate and quality of life of patients while prolonging their survival.",[27],[27],"2024-10-25",{"date":299,"type":32},"2024-10-28",{"date":301,"type":20},"2024-10-15",{"date":303,"type":20},"2025-10-15",{"name":305,"class":67},"Second Xiangya Hospital of Central South University",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100523976","the-efficacy-and-safety-of-fluzopril-combined-with-apatinib-in-maintenance-treatment-of-platinum-resistant-recurrent-ovarian-cancer-patients-100523976","NCT06102707","The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients","Inclusion Criteria:\n\n1. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.\n2. Female, age ≥ 18 years old (calculated based on the date of signing informed consent).\n3. High grade (or medium to low differentiation) serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by pathology; Or moderately or poorly differentiated ovarian endometrioid adenocarcinoma. Disease progression occurred within 6 months (182 days) of the last platinum containing chemotherapy.\n4. Received at least 3 cycles of chemotherapy.\n5. After the completion of chemotherapy treatment, it is evaluated as non disease progression and must be randomly enrolled within 6 weeks after the last dose of chemotherapy is administered.\n6. Must be able to provide tumor tissue samples fixed with formalin and embedded in paraffin (FFPE).\n7. The Eastern Cooperative Oncology Group score is 0-1.\n8. The function of important organs meets the following requirements (no blood components or cell growth factors are allowed to be used within the first 14 days of randomization):absolute neutrophil count ≥ 1.5 × 109\u002FL; Platelets ≥ 100 × 109\u002FL; Hemoglobin ≥ 90g\u002FL;Serum albumin ≥ 3g\u002FdL;Bilirubin ≤ 1.5 times ULN;ALT and AST ≤ 3 times ULN; Serum creatinine ≤ 1.5 times ULN.\n9. Patients with potential fertility need to use at least one medically approved contraceptive method (such as an intrauterine device or condom) during the study treatment period and within 3 months after the end of the study treatment period, and must have a negative serum HCG test within 72 hours before randomization; And it must be non lactating.\n\nExclusion Criteria:\n\n1. Subjects had other malignant tumors in the past (within 5 years) or at the same time, except for cured skin basal cell carcinoma, cervical carcinoma in situ and breast cancer that had no recurrence for more than 3 years after the completion of radical surgery.\n2. Previously used both PARP inhibitors and small molecule VEGF inhibitors, including but not limited to olaparib, nilaparib, arotinib, apatinib, etc; Single drug treatment can be included in the group.\n3. Patients with untreated central nervous system metastasis who have previously received systemic or curative brain or meningeal metastasis treatment (radiotherapy or surgery), and have been confirmed stable by imaging for at least 1 month, and have stopped systemic hormone therapy (dosage\\>10mg\u002Fday of prednisone or other effective hormones) for more than 2 weeks, without clinical evidence, can be included.\n4. Patients who have recently experienced intestinal obstruction or gastrointestinal perforation (within 3 months).\n5. Patients who are unable to swallow tablets normally or have gastrointestinal dysfunction, as determined by the researchers, may affect drug absorption.\n6. Patients with clinical symptoms of cancerous ascites or pleural effusion who require puncture or drainage, or who have received ascites or pleural effusion drainage within the first 3 months of randomization.\n7. Patients with clinically uncontrolled cardiac symptoms or diseases, such as NYHA grade 2 or above heart failure, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, and QTc\\>470ms.\n8. Patients with hypertension who cannot achieve good control after treatment with antihypertensive drugs (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg).\n9. Any bleeding event with a severity rating of 2 or above in CTCAE 5.0 within the first 4 weeks of randomization.\n10. Previous or current history of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, tissue pneumonia (such as bronchitis, occlusive vasculitis), drug-induced pneumonia, or screening stage CT showing active pneumonia.\n11. Individuals with abnormal coagulation function (INR\\>1.5 or prothrombin time\\>ULN+4 seconds), bleeding tendencies, or undergoing thrombolytic or anticoagulant treatment are allowed to receive low-dose low-molecular-weight heparin or oral aspirin for prophylactic anticoagulant treatment during the trial period.\n12. There have been incidents of arterial\u002Fvenous thrombosis within the first 6 months of randomization, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism.\n13. Patients with a history of hereditary or acquired hemorrhagic disease or coagulation disorders. Within the first 3 months of randomization, there were significant clinically significant bleeding symptoms or clear bleeding tendencies, such as gastrointestinal bleeding, hemorrhagic gastric ulcers, etc.\n14. Subject has active infection or unexplained onset of ≥ 38.5 ° C within 7 days prior to randomization.\n15. Subjects have congenital or acquired immune deficiency (such as HIV infected persons), or active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500IU\u002Fml; hepatitis C reference: HCV antibody positive and HCV copy number\\>upper limit of normal value).\n16. Patients who have received surgery, radiation therapy, chemotherapy, and endocrine therapy before randomization for less than 4 weeks after treatment completion; Adverse events caused by previous treatment (excluding hair loss) that have not recovered to ≤ 1 level (CTCAE 5.0).\n17. Patientss who may receive other systemic anti-tumor treatments or plan to undergo ovarian cancer reduction surgery during the study period.\n18. According to the judgment of the researchers, there are other factors that may lead to the forced termination of this study, such as other serious illnesses (including mental illness) requiring concurrent treatment, serious laboratory test abnormalities, accompanied by family or social factors, which may affect the safety of the subjects, or the collection of data and samples.",{"count":313,"type":20},50,[315],"NA","Ovarian cancer is the most lethal gynecological malignancy, posing a serious threat to women's health worldwide.Platinum resistant ovarian cancer is the biggest challenge faced by gynecological oncologists.Exploring more effective treatment options and how to delay the recurrence of platinum resistant recurrent ovarian cancer remains a challenging issue in clinical treatment.The main goal of this trial is to evaluate the effectiveness and safety of fluzopril combined with apatinib in maintenance treatment of platinum resistant recurrent ovarian cancer patients by evaluating progression free survival (PFS).Fifty patients with advanced ovarian cancer who underwent platinum resistant recurrent chemotherapy and assessed no disease progression were enrolled in the study, and maintenance treatment was performed with fluzopril combined with apatinib.",[27],"2023-10-22",{"date":320,"type":32},"2023-10-26",{"date":322,"type":20},"2023-11-01",{"date":324,"type":20},"2026-11-01",{"name":326,"class":67},"Qilu Hospital of Shandong University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":270,"enrollmentInfo":334,"targetDuration":4,"studyType":21,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":262},"100361213","phase-2-surgery-and-niraparib-in-secondary-recurrent-ovarian-cancer-soc-3-trial-100361213","NCT03983226","Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)","A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Age ≥18 years to ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Patients with platinum-sensitive, secondary relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.\n* Front-line or second-line treatment may have included maintenance therapy (i.e. bevacizumab, PARP inhibitor)\n\n  * Cohort 1 and Cohort 3: No prior use of PARP inhibitor.\n  * Cohort 2: Prior use of PARP inhibitor.\n  * Cohort 3: No prior use of PARP inhibitor.\n* Secondary cytoreductive surgery (SCR) when first recurrence\n\n  * Cohort 1 and Cohort 2: Never received SCR\n  * Cohort 2: Never received SCR\n  * Cohort 3: Received SCR\n* Assessed by the experienced surgeons, complete resection of all recurrent disease is possible. Single or localized lesions identified by CT, or MRI, or positron emission tomography\u002Fcomputed tomography (PET\u002FCT). PI and Co-PI reach consensus if extensive lesions or carcinomatosis.\n* It can be included if single lesion outside the peritoneal cavity can be resected.\n* No more than 3 disease lesions by central-reviewed PET\u002FCT imaging if the participated center has never participated in any surgical trials on ovarian cancer before.\n* Patients who have given their signed and written informed consent and their consent.\n\nExclusion Criteria:\n\n* Patients with borderline tumors as well as non-epithelial tumors.\n* Patients for interval-debulking, or for second- or third-look surgery, or palliative surgery planned.\n* Impossible to assess the resectability. Radiological signs suggesting complete resection is impossible.\n* Patients who have received more than two previous regimen of chemotherapy (maintenance is not considered a third regimen).\n* Third relapse or more.\n* Patients with second or other malignancies who have been treated by surgery, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected.\n* Progression during chemotherapy or recurrence within 6 months after second-line platinum-based therapy\n* Any contradiction not allowing surgery and\u002For chemotherapy and\u002For or Niraparib\n* Accompanied by hypoxia serious chronic obstructive pulmonary disease\n* Uncontrolled hypertension, cerebrovascular accident\u002F Stroke, myocardial infarct, unstable angina, untreated thrombosis, chronic congestive heart failure, or serious arrhythmia in need of medicine.\n* Severe hepatitis, history of liver disease, nephrotic syndrome, renal insufficiency\n* Active ulcer history, abdominal wall fistula, perforation of gastrointestinal tract, or Intra-abdominal abscess, or simultaneously apply treatment\u002Fprevent ulcers therapy.\n* Uncontrolled diabetes\n* Uncontrolled epilepsy need long-term antiepileptic treatment.\n* Any medication induced considerable risk of surgery, e.g. estimated bleeding due to oral anticoagulating agents.\n* ≥3 grade anemia, neutropenia or thrombocytopenia due to chemotherapy, and lasted for more than 4 weeks\n* Patients with a known hypersensitivity to Niraparib or any of the excipients of the product.",{"count":335,"type":20},167,[24],"This is a Phase II, open-label, multicenter, randomized umbrella study to evaluate the efficacy of cytoreductive surgery and Niraparib maintenance in participants with platinum-sensitive secondary recurrent ovarian cancer. Cohort 1 will focus on participants without prior use of PARP inhibitor, and without prior secondary cytoreduction (SCR) when first recurrence. Cohort 2 will focus on participants with prior use of PARP inhibitor, but without prior SCR when first recurrence. Cohort 3 will focus on participants with SCR when first recurrence, but without prior use of PARP inhibitor.",[27,339,340],"Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[342,343,344,345],"reurrent Ovarian Cancer","Secondary Cytoreductive Surgery","Chemotherapy","Niraparib maintenance","2022-03-04",{"date":348,"type":32},"2022-03-18",{"date":350,"type":32},"2019-10-18",{"date":352,"type":20},"2026-12",{"name":354,"class":355},"Shanghai Gynecologic Oncology Group","OTHER_GOV"]